Pros | - | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 227 Cr | 8357 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.89% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 43 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.6%) Divi's Laboratories Ltd (8.38%) Apollo Hospitals Enterprise Ltd (5.96%) Max Healthcare Institute Ltd Ordinary Shares (5.89%) Torrent Pharmaceuticals Ltd (4.53%) | Sun Pharmaceuticals Industries Ltd (11.94%) Divi's Laboratories Ltd (7.34%) Cipla Ltd (6.09%) Lupin Ltd (6.09%) Apollo Hospitals Enterprise Ltd (5.91%) | ||
No of Sectors | 4 | 1 | ||
Top 3 Sectors | Health (92.62%) Basic Materials (4.08%) Industrial (2.03%) | Health (100%) | ||
Equity % | 97.87% | 99.48% | ||
Debt % | - | - | ||
P/E | 42.25 | 36.11 | ||
P/B | 6.26 | 5.78 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.77% | -0.19% | ||
3-Month Return | 0.79% | 0.64% | ||
6-Month Return | 11.85% | 12.17% | ||
1-Year Return | -2.01% | -0.52% | ||
3-Year Return | 24.51% | 25% | ||
5-Year Return | - | 19.15% |
Sharpe | 0.98 | 1.06 | ||
Alpha | 1.7 | 0.66 | ||
Beta | 0.9 | 0.91 | ||
Standard Deviation | 15.6 | 15.05 | ||
Information Ratio | 0.11 | -0.24 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Rohan Korde,Dhimant Shah | Sailesh Raj Bhan,Kinjal Desai |